SNPs in COX-1, COX-2, LOX isoforms, and TP53 should be further evaluated as biomarkers of aspirin chemoprevention efficacy, alone and in combination with other polymorphisms reported to predict colorectal polyp and/or colorectal cancer risk reduction by aspirin (3). This evidence concerns the gene LOX and colorectal cancer.